UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 451

Sortiert nach

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

Journal of clinical oncology, 2017-06, Vol.35 (17), p.1884-1890

2017

Volltextzugriff (PDF)

A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5003-5003

2016

Volltextzugriff (PDF)

Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy

Journal of clinical oncology, 2015-02, Vol.33 (6), p.582-587

2015

Volltextzugriff (PDF)

Second cancers after hematopoietic stem cell transplantation with total body irradiation conditioning regimen in hematologic disorders

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6548-6548

2011

Volltextzugriff (PDF)

A phase I study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS2602-TPS2602

2015

Volltextzugriff (PDF)

Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4543-4543

2018

Volltextzugriff (PDF)

A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS2636-TPS2636

2014

Volltextzugriff (PDF)

RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.501-501

2018

Volltextzugriff (PDF)

RXÂ 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancerâ€“Preliminary results of stage II of the phase Ia/IIb study

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.396-396

2018

Volltextzugriff (PDF)

Prognostic impact of immunohistochemical expression of Ki-67 in patients with advanced gastric cancer who underwent curative resection

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.19-19

2011

Volltextzugriff (PDF)

Phase I dose-finding study of epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer (AGC)

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.123-123

2011

Volltextzugriff (PDF)

Combining pembrolizumab and palliative radiotherapy in gastroesophageal cancer to enhance anti-tumor T-cell response and augment the abscopal effect

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.TPS220-TPS220

2017

Volltextzugriff (PDF)

A phase 1 study of p53MVA vaccine in combination with pembrolizumab

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.206-206

2018

Volltextzugriff (PDF)

A pilot study of vinorelbine safety and pharmacokinetics (PKs) in patients (pts) with varying degrees of liver dysfunction (LD)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.432-432

2018

Volltextzugriff (PDF)

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.460-460

2023

Volltextzugriff (PDF)

Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7035-7035

2010

Volltextzugriff (PDF)

Reversal of titanium-induced myelofibrosis

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.18028-18028

Chung, H. M.

2008

Volltextzugriff (PDF)

A randomized phase II study of biweekly irinotecan versus irinotecan plus 5-fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14511-e14511

2010

Volltextzugriff (PDF)

Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4544-4544

2017

Volltextzugriff (PDF)

The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.345-345

2022

Volltextzugriff (PDF)

The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.333-333

2022

Volltextzugriff (PDF)

Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4126-4126

2018

Volltextzugriff (PDF)

Multiomic molecular comparison of primary versus metastatic pancreatic tumors

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.213-213

2018

Volltextzugriff (PDF)

Integration of palliative care for patients with solid tumors on phase I clinical trials

Journal of clinical oncology, 2016-10, Vol.34 (26_suppl), p.138-138

2016

Volltextzugriff (PDF)

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4154-TPS4154

2018

Volltextzugriff (PDF)

1 – 25 von 451

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Online Journals

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(451)
Mit Volltextzugriff
(448)

Publikationsform

Artikel
(451)

Sprache

Englisch
(451)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Oncology
(61)
Life Sciences & Biomedicine
(59)
Science & Technology
(59)
Humans
(57)
Female
(43)
Male
(43)
Middle Aged
(41)
Aged
(39)
Adult
(33)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Original Reports
(20)
Aged, 80 And Over
(19)
Tumors
(18)
Neoplasm Staging
(14)
Prognosis
(14)
Survival Rate
(13)
Treatment Outcome
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Disease-Free Survival
(9)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

J Clin Oncol
(1)

Menü

Weitere Dienste

Einstellungen

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer

Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy

Second cancers after hematopoietic stem cell transplantation with total body irradiation conditioning regimen in hematologic disorders

A phase I study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC)

A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC)

RXÂ 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancerâ€“Preliminary results of stage II of the phase Ia/IIb study

Prognostic impact of immunohistochemical expression of Ki-67 in patients with advanced gastric cancer who underwent curative resection

Phase I dose-finding study of epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer (AGC)

Combining pembrolizumab and palliative radiotherapy in gastroesophageal cancer to enhance anti-tumor T-cell response and augment the abscopal effect

A phase 1 study of p53MVA vaccine in combination with pembrolizumab

A pilot study of vinorelbine safety and pharmacokinetics (PKs) in patients (pts) with varying degrees of liver dysfunction (LD)

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study

Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor

Reversal of titanium-induced myelofibrosis

A randomized phase II study of biweekly irinotecan versus irinotecan plus 5-fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer

Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study

The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma

The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience

Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program

Multiomic molecular comparison of primary versus metastatic pancreatic tumors

Integration of palliative care for patients with solid tumors on phase I clinical trials

A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response

Aktive Filter

Suchergebnisse filtern